2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 262

Canakinumab Therapy in Patients with Familial Mediterranean Fever
Abstract Number: 290

Cancer and Necrotizing Immune Mopathy: High Incidence in Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Positive and Seronegative Patients but Not in Anti-Single Recognition Particle Positive Patients
Abstract Number: 955

Cancer Risk in 5,108 Patients with Juvenile Idiopathic Arthritis (JIA)
Abstract Number: 2255

Capillaroscopic Patterns in a Healthy Population
Abstract Number: 3103

Carbamylated Human Albumin Is One of the Target Antigens of Anti-Carbamylated Protein Antibodies
Abstract Number: 1581

Cardiac Involvement in Patients with Amyloid a Amyloidosis Due to Rheumatoid Arthritis
Abstract Number: 2586

Cardiac Magnetic Resonance Imaging Reveals Myocardial Damage in Patients with Active Rheumatoid Arthritis
Abstract Number: 3064

Cardiac Manifestation of Takayasu Arteritis
Abstract Number: 1568

Cardiac Morphology and Function in Patients with Acute Coronary Syndrome Complicated with Rheumatoid Arthritis
Abstract Number: 2972

Cardiopulmonary Exercise Testing in Patients with Systemic Sclerosis: Unexplored Mechanisms of Dyspnea
Abstract Number: 1972

Cardiovascular and Cerebrovascular Disease and Social Deprivation in Patients with Giant Cell Arteritis
Abstract Number: 1604

Cardiovascular Disease in a Large Incident Cohort of Early Inflammatory Arthritis
Abstract Number: 37

Cardiovascular Disease in Immune-Mediated Inflammatory Diseases: Cross Sectional Analysis of the Influence of Demographic and Traditional Cardiovascular Risk Factors
Abstract Number: 2270

Cardiovascular Disease: The Hidden Risk in Persons with Rheumatoid Arthritis
Abstract Number: 2578

Cardiovascular Effects of Etanercept in an Animal Model of Rheumatoid Arthritis: Mechanisms Involved

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].